AtriCure, Inc. (ATRC) Fair Value 2026

ATRC · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.8 /10

32 fundamental signals · 7 models active

Value Trap Risk

SAFE (6/100)

Quick Summary — As of 2026-10-07, AtriCure, Inc. (ATRC) trades at $53.68, versus a $14.71 median fair value across its 7 active models — 72.6% below the current price. QOC: 7.8/10. Value Trap Risk: 6/100 (SAFE). 7/13 models active. Within that set, the Bayesian DCF component alone returns $14.71.

Key Facts

Ticker
ATRC
Price
$53.68
Quality Score
7.8/10
Value Trap Risk
6/100
Models Active
7/13
Last Updated
Strength: 7 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is AtriCure, Inc. (ATRC) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, AtriCure, Inc. (ATRC) appears overvalued as of : the median of 7 independent fair value estimates is $14.71, 72.6% below the current price of $53.68. Estimates range from $2.99 to $16.91. ATRC scores 7.8/10 on fundamental quality and 6/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -20.1% versus its own 13-model consensus, across 3,777 rated companies as of 2026-10-07. ATRC’s -72.6% gap is wider than that market norm, and the Medical Instruments & Supplies sector median is -28.2%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy AtriCure, Inc. Stock in 2026? →

What Fair Value Does Each Model Give ATRC?

7 Intrinsic Value Models vs. Current Price ($53.68)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $14.71 -72.6%
Ensemble · Medium Conviction
 $14.09 -73.8%
Scenario · High Conviction
 $16.46 -69.3%
Unlock the Full Matrix

Access 4 additional models including Regime Cross-Sectional, Sentiment SOTP, and more.

$2 / day

Billed monthly ($60/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is ATRC's Fair Value Range?

Spread across 7 independent models · $2.99 to $16.91

CirclFi's 7 active models place AtriCure, Inc. (ATRC) between $2.99 and $16.91 per share, a spread of 95% of the median. The median of that range — $14.71 — is the fair value CirclFi publishes for ATRC, against a current price of $53.68.

Low · Sentiment SOTPHigh · Regime Cross
$2.99median $14.71$16.91
Where the range comes from
Most bearish modelSentiment SOTP$2.99
Most bullish modelRegime Cross-Sectional$16.91
Model agreement0 bullish · 7 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on ATRC, not a CirclFi price target. How each model works →

What Is AtriCure, Inc. (ATRC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, AtriCure, Inc.'s intrinsic value is estimated at $14.71. Trading at its current price of $53.68, the valuation engine raises significant caution: 7 of 7 models flag downside risk, projecting a median implied return of -72.6%. Among models with highest confidence, Bayesian DCF lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About ATRC?

7 of 13 models are currently active for ATRC. All 7 active models suggest the stock trades above fair value. Taken together, their median fair value for ATRC is $14.71 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $14.71 on its own, implying -72.6% downside from the current price. See which stocks rank higher →

How Does ATRC Rank in Medical Instruments & Supplies?

Among 54 Medical Instruments & Supplies stocks, ATRC ranks #16 by Quality of Company score. CirclFi's QOC score of 7.8/10 evaluates 32 fundamental signals. A score of 7.8 indicates above-average quality.

See all Most Undervalued Medical Instruments & Supplies Stocks →

AtriCure, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is ATRC a Value Trap?

CirclFi's Value Trap algorithm assigns ATRC a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for AtriCure, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, AtriCure, Inc. earns a quality score of 7.8/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

Models cluster within a tight range (+25.9% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ATRC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ATRC's 7 active models, average confidence is 48%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy AtriCure, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

10 related Medical Instruments & Supplies stocks with 13-model coverage

EMBCEmbecta Corp.QOC 7.8STVNStevanato Group S.p.A.QOC 7.7RGENRepligen CorporationQOC 8.0MDLNMedline Inc.QOC 7.7UTMDUtah Medical Products, Inc.QOC 8.2WRBYWarby Parker Inc.QOC 7.6MMEDMiniMed Group, Inc.QOC 6.6CUPRCuprina Holdings (Cayman) LimitedQOC 5.6RMDResMed Inc.QOC 9.4ISRGIntuitive Surgical, Inc.QOC 9.4

Read investment analysis: EMBC · STVN · RGEN · MDLN · UTMD · WRBY · MMED · CUPR · RMD · ISRG

Which Other Stocks Have a Similar Quality Score to ATRC?

7 companies across all industries closest to ATRC’s Quality of Company score of 7.8/10.

AGOAssured Guaranty Ltd.QOC 7.8APIAgora, Inc.QOC 7.8LWLamb Weston Holdings, Inc.QOC 7.8MBCMasterBrand, Inc.QOC 7.8NKSHNational Bankshares, Inc.QOC 7.8KLICKulicke and Soffa Industries, Inc.QOC 7.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AGO · API · LW · MBC · NKSH · KLIC · NVDA

Where Does ATRC Sit in CirclFi's Medical Instruments & Supplies Rankings?

ATRC is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About AtriCure, Inc.’s Valuation?

What is AtriCure, Inc.'s intrinsic value in 2026?

CirclFi puts AtriCure, Inc. (ATRC)'s intrinsic value at $14.71 — the median of 7 independent model estimates as of 2026-10-07, ranging from $2.99 to $16.91. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $14.71 on its own. The Quality of Company score is 7.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ATRC overvalued or undervalued right now?

At $53.68, 0 of 7 active models suggest ATRC may be undervalued, while 7 indicate potential overvaluation. The median of all 7 fair value estimates is $14.71, 72.6% below the current price of $53.68 — a consensus view that ATRC is overvalued. The assessment depends on which methodology best fits AtriCure, Inc.'s business model in Medical Instruments & Supplies.

What does a Quality of Company score of 7.8 mean for ATRC?

AtriCure, Inc.'s QOC of 7.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on ATRC?

CirclFi analyzes ATRC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ATRC?

Of the 7 models currently active on ATRC, Regime Cross-Sectional is the most bullish at $16.91 per share, and Sentiment SOTP is the most bearish at $2.99. CirclFi's published fair value for ATRC is the median of that range, $14.71, not either extreme. The gap between the two ends equals 95% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is ATRC a value trap in 2026?

AtriCure, Inc.'s Value Trap score is 6/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 7-model valuation engine, AtriCure, Inc. (ATRC) has a median fair value of $14.71 — 72.6% below the current price of $53.68 — as of 2026-10-07.” Source: circlfi.com/stock/ATRC/ · Methodology
Primary sources for this ATRC valuation
  • Financial statements: AtriCure, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001323885) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ATRC as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on ATRC.

Unlock All 7 Fair Values — $60/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for ATRC Unlock All 7 — $60/mo